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ABSTRACT
The assessment of breast cancer relative morbidity risk in women taking oral contraceptives (OC) or hormone 
replacement therapy (HRT) — currently known as menopausal hormone therapy — is still a challenge. The analysed 
groups of women vary widely depending on the type, route of application and doses of hormones, the duration of 
administration, and the time from therapy cessation. Moreover, the risk of breast cancer depends on the patient’s 
genetic predisposition, and for this reason the analyses of OC and HRT should be performed separately in the 
group of healthy women, in BRCA1/2 mutation carriers, and in breast cancer survivors. This paper was aimed to 
analyse the safety of OC and HRT in three groups of women depending on the risk of breast cancer development 
(healthy women) or breast cancer recurrence (breast cancer survivors).
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Introduction
Oestrogens are established mitogen factors affecting 
epithelial breast cells; however, their mechanism of ac-
tion was recognised only recently. Initially it was thought 
that progestogens act on breast cells and endometrium 
in similar patterns; however, physiologically the high-
est proliferation of breast cells is observed during the 
luteal phase of the menstrual cycle, e.g. with high levels 
of oestrogens as well as progestogens. The proliferation 
rate, reflected by the Ki-67/MIB-1 level, is higher in 
patients taking oral contraceptives than in women with 
natural menstruation [1]. 
Although the molecular mechanisms of the carcino-
genic effects of oral contraceptives (OC) and hormone 
replacement therapy (HRT) — the current name meno-
pausal hormone therapy (MHT) — in breast are not com-
pletely understood, it seems that oestrogens and progesta-
gens contribute to cancer promotion and acceleration of 
cancer manifestation. Hormones act on already abnormal 
epithelial breast cells and all steps of carcinogenesis are 
completed with the ultimate development of cancer and 
its manifestation during OC or HRT [2]. These sugges-
tions are supported by the results of some trials showing 
that breast cancers are diagnosed usually one year after 
initiating of OC and HRT, but 10 years after cessation 
of therapy the risk returns to baseline [3, 4]. 
The assessment of breast cancer relative morbidity 
risk in women taking OC or HRT is a challenge. The 
analysed groups of women widely vary depending on the 
type of hormones used (oestrogens alone vs. oestrogens 
combined with progestogens), the route of their appli-
cation [pills, transdermal patches, intra-uterine devise 
(IUD)] and dose, the duration of administration, and the 
time after therapy cessation. It should be underlined that 
the risk of breast cancer development should be analysed 
separately in the group of healthy women, in BRCA1/2 mu-
tation carriers, and in patients with breast cancer.
The aim of the study was to discuss the indica-
tions to OC and HRT in relation to the risk of breast 
cancer development (healthy women) or breast cancer 
progression (breast cancer patients). Additionally, the 
recommendations regarding the use of OC and HRT in 
different risk groups were presented.
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Oral contraception and breast cancer
Combined oral contraception (COC), containing 
oestrogens and progestogens, is one way of family plan-
ning, and this has been used since the 1960s. Approxi-
mately 20% of women using contraception worldwide 
choose these pills. Among women in the age from 25 to 
35 years this percentage is 33% [5], and in the Polish 
population it is approximately 39% [6].
The goal and the main benefit of using OC is the limi-
tation of unintended pregnancies, but it also decreases the 
percentage of extrauterine pregnancies, ovarian cysts and 
ovarian cancers, endometriosis and endometrial cancer, 
as well as colorectal cancer (CRC) [7]. The protective 
role of OC in ovaries possibly results from inhibition of 
ovulation. On the other side, OC could simultaneously 
increase the risk of cardiovascular diseases, cervical can-
cer (particularly in HPV infected women) [7], and breast 
cancer [2, 8–13]. Increased production of coagulation 
proteins in the liver caused by oestrogens and unfavour-
able serum lipids profile related to progestagens, leads 
to a 3–4-fold increased risk of thromboembolic events 
(stroke in particular). Thromboembolic risk is especially 
high in women with additional factors of cardiovascular 
diseases risk, like smoking or suffering from migraines [9]. 
Taking into consideration that the risk of thrombo-
embolic event and breast cancer development depends 
on the dose of oestrogens and progestagens, in the 
1960s the daily dose of OC was decreased from 150 μg 
of mestranol to 20–35 μg of metynyloestradiol [9] and 
from 9.85 mg norethynodrel to less than 1 mg of differ-
ent progestogens [14].
Hormone contraception and the risk of breast 
cancer development in an unselected healthy 
female population
The very first meta-analysis of 54 studies, including 
53.297 female breast cancer patients and 100.239 healthy 
women in 25 countries (90% of all available data 
concerning OC and breast cancer) was published in 
1996, and it found that the relative risk (RR) of breast 
cancer development in women currently using OC was 
1.24 (p < 0.00001) [14] and decreased together with 
prolongation of time since termination of OC. The risk 
after 1–4 years from OC cessation RR was 1.16, and 
after 5–9 years it was 1.07. No increased risk of breast 
cancer was noted after 10 years since permanent dis-
continuation of OC. 
In 2007 an updated meta-analysis of current clini-
cal trials was published (studies with lower hormone 
doses were included) [15]. Relative risk of breast cancer 
development in women using OC at any time was 1.19, 
and it was higher in women taking OC before first-term 
pregnancy (1.44), than in women after pregnancy (1.15). 
This observation supports the unfavourable influence of 
OC on breast before its development process is finished 
and shows the need for careful observation of very young 
women using OC. Fortunately, the absolute increase 
of breast cancer morbidity was very low, resulting from 
a low rate noted in young women. 
A meta-analysis of over 100 non-randomised clini-
cal trials evaluating correlation between OC and the 
development of different cancers, including 44 studies 
with breast cancer patients, was published in 2013 and 
confirmed numerically low, but statistically impor-
tant, increasing of risk of breast cancer development 
(HR = 1.08) [7]. Table 1 summarises the results of the 
meta-analyses.
In conclusion, the analysis of unselected cohorts of 
healthy women indicated that oral hormone contracep-
tion in currently used low doses is correlated with slightly 
increased risk of breast cancer development.
Hormone contraception in healthy women with 
family history of breast/ovarian cancer and in 
BRCA1/2 mutation carriers
The study including women with positive family his-
tory of breast/ovarian cancer, taking OC before 1975 in 
a dose exceeding 50 μg of ethinyloestradiol per day, 
indicated a 3–11-fold increased risk of breast cancer 
development, proportionally to the number of family 
members suffering from this cancer [16]. In 2009 a me-
ta-analysis of 12 clinical studies with OC in women with 
positive family history of breast cancer was published, 
which indicated increased risk of breast cancer develop-
ment only in the subgroup of women taking OC before 
Table 1. Relative risk of breast cancer development after oral contraceptive
Stosowanie COC Meta-analysis 1996 [14] Meta-analysis 2013 [7]
Relative risk Relative risk
Currently using COC 1.24 1.08
14 years after cessation 1.16 1.21
5–9 years after cessation 1.07 1.17
10–20 years after cessation 1.01 1.13
> 20 years after cessation – 1.02
COC — combined oral contraception
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1975. This correlation was not observed in women using 
more modern hormonal formulations [17–19]. 
The risk of breast cancer development in patients 
with BRCA1 and BRCA2 gene mutations, who use OC, 
is still a matter of controversy [20, 21]. A meta-analysis 
of 18 clinical trials, including women with BRCA1/2 gene 
mutations, published in 2010, indicated that the rela-
tive risk in women taking OC before 1975 was 1.47, 
but in women using newer hormone pillsit was lower 
(RR = 1.17) [13]. There were no differences between 
carriers of BRCA1 and BRCA2 gene mutations 
(RR = 1.09 and RR = 1.15, respectively). To note, 
OC decreased risk of ovarian cancer (RR = 0.50) and 
this protective effect intensified with time [13]. This is 
important information for physicians involved in genetic 
counselling, who present the risks and benefits of OC 
and HRT use to healthy carriers of BRCA1/2 gene mu-
tations, who are at very high risk of breast cancer and 
ovarian cancer development.
There are no consistent statements from the World 
Health Organisation (WHO) and the American College 
of Obstetricians and Gynaecologists (ACOG) regard-
ing the use of oral contraception in relation to the risk 
of breast cancer development. According to the WHO 
recommendations, using of OC do not increase the 
risk of breast cancer development in healthy women 
with positive family history and/or carrying germinal 
mutations known to be related to breast cancer [19]. 
According to the ACOG, positive family history regard-
ing breast cancer is not a contraindication to use of OC. 
However, patients with BRCA1/2 gene mutations are at 
higher risk of breast cancer development if they are us-
ing OC for more than five years before 30 years of age, 
with simultaneously decreased risk of ovarian cancer 
development [19].
Hormone contraception in women with breast 
cancer
According to the evidence regarding breast cancer 
pathophysiology, the WHO does not recommend hor-
mone contraceptive methods in patients with this cancer, 
because of the risk of disease recurrence and intensifi-
cation of thromboembolic complications [22]. Patients 
with breast cancer are advised to use hormone-free in-
trauterine contraception. There is no consensus regard-
ing a uniform opinion about the safety of intrauterine 
contraception with progestogens (levonorgestrel) in that 
group of patients [23]. 
Who is the best candidate for 
hormone contraception?
As the risk of breast cancer development is not 
consistent in overall female population, the decision 
regarding using of OC should be based on individualized 
analysis of benefits and risks related to hormones. Wom-
en should review together with physician all risk factors 
for breast cancer development (life style — alcohol 
consumption and obesity; reproduction — age of me-
narche and first childbirth as well as breastfeeding) 
as well as inherited predisposition to breast cancer 
development (family history regarding breast/ovarian 
cancer, carrying state of BRCA1/2 mutations) [24]. 
Additionally, the history regarding cardiovascular dis-
eases (tobacco smoking, hypertension, diabetes, heart 
failure, cerebrovascular diseases, migraine, family his-
tory regarding myocardial infarction, thrombosis, lung 
embolism, stroke and inherited coagulation disorders, 
levels of serum cholesterol fractions) should be taken 
and individual risk should be established. 
The woman deciding to use OC should be informed 
about danger of tobacco smoking (increases the risk of 
thromboembolic complications), advised about regular 
gynecological visits together with cervical cytology and 
examination of breasts in order to early diagnose poten-
tial abnormalities [12]. Healthy women could use OC till 
menopause or, after finishing of procreation period the 
contraception method could be change [10]. In women 
with migraine and smokers the termination of OC in 
35 year of age should be discussed, as after this the risk of 
thromboembolic complications is significantly increased. 
There is no data regarding the risk of OC complications 
in very young women, so there is difficult to establish 
appropriate period of OC use in this subgroup. The 
women with heart failure, coronary artery disease, 
cerebrovascular diseases and breast cancer should be 
advised to use other contraception method. 
Healthy women, carriers of BRCA1/2 genes muta-
tions should be familiarized with increased risk of breast 
cancer development after OC, particularly if it is used 
longer than 5 years in younger age, before the first 
pregnancy. The decision regarding OC usage should 
be made after consultation of genetic counselling cen-
tres. Given the significant controversies regarding the 
risk of using OC by carriers of BRCA1/2 genes muta-
tions, some genetic counselling centres advise not to use 
this contraception method.
Hormone contraception — summary
1. Modern, low-dose, oral hormone contraception 
used in healthy women with average risk of breast 
cancer and cardiovascular diseases remains safe and 
efficient birth control method. In these populations 
the risk of breast cancer development is low.
2. Using of oral hormone contraceptives in health 
female carriers of BRCA1/BRCA2 gene mutations 
is still the subject of controversial debate taking 
into consideration increased risk of breast cancer 
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development and decreased risk of ovarian cancer 
mortality. 
3. Oral hormone contraception is not recommended 
in breast cancer patients. It is suggested using 
another method of birth control in this population 
(intra-uterine device, IUD).
Hormone replacement therapy 
(menopausal hormone therapy)  
and breast cancer
Hormone replacement therapy (menopausal 
hormone therapy) and a risk of breast cancer  
in unselected healthy women population
Hormone replacement therapy (HRT), currently 
known as menopausal hormone therapy (MHT), was 
initially introduced in order to control vasomotor 
symptoms of menopause, since estrogens administra-
tion is the most efficient way to alleviate most common 
abnormalities (hot flushes, night sweats, tachycardia, 
headache and dizziness, fatigue, anxiety, depression, 
sleep disorders) as well as genitourinary symptoms, con-
nected to epithelial atrophy (vaginal dryness and itching, 
increased frequency of urination [pollakiuria]). Sixty 
years after HRT introducing, perimenopausal symptoms 
still remain the most important justification of its use, 
particularly in women before 60 years or during first 
10 years after menopause [25–28]. 
The second indication to HRT is fracture preven-
tion during osteoporosis, especially in women before 
60 years or during first 10 years after menopause [25–29]. 
However, HRT is not recommended in all patients with 
osteoporosis, regarding side effects and availability of 
other effective methods for treatment of this disease. 
HRT could be used in selected patients, with failure 
after alternative drugs administration.
As 5-fold increasing of the risk of endometrial cancer 
development was revealed as one of the side effects 
of estrogens administration, since ‘70s of last century 
progestogens were added to estrogens, hereby initiating 
the era of combined, two-component estrogen–progre-
stagen hormone replacement therapy [30]. 
In 1997 meta-analysis was performed, including 
51 clinical trials presenting correlations between HRT 
and a risk of breast cancer development. Evaluated stud-
ies comprised approximately 90% of available scientific 
literature regarding this topic. The analysis included 
53.865 postmenopausal women, of whom 17.830 (33%) 
had used HRT [31]. In women using HRT for 5 years or 
longer the relative risk of breast cancer development was 
increased (RR = 1.35). Five years after HRT cessation 
breast cancer risk returned back to baseline.
In cohort Million Women Study [32], including over 
1 million women participated in breast cancer skreening, 
the relative risk of breast cancer development in women 
currently using HRT was 1.66 (p < 0.0001), and the risk 
of death due to breast cancer was 1.22 (p = 0.05). It 
was no increased risk of breast cancer development in 
women previously using HRT (RR = 1.01). Relative risk 
of breast cancer was significantly higher in women tak-
ing estrogens combined with progestogens (RR = 2.0, 
p < 0.0001) as compared to women taking estrogens 
alone (RR = 1.30, p < 0.0001). Absolute risk of breast 
cancer development after the use of estrogens combined 
with progestogens was 6/1000, and after estrogens alone 
1.5/1000 (Table 2).
The most important clinical trials addressing the 
role of HRT in breast cancer development were 2 rand-
omized studies, conducted by Women’s Health Initiative 
(WHI) in 40 sites in United States [33–45]. The first 
trial analysed the role of estrogens alone (conjugated 
equine estrogens in daily dose of 0.625 mg vs. placebo) 
in women after hysterectomy (10.739 women), and the 
second one was aimed to assess the role of estrogens 
and progestagens (conjugated equine estrogens in daily 
dose of 0.625 mg and medroxyprogesterone acetate in 
daily dose of 2.5 mg vs. placebo) in women with repro-
ductive organs preserved (16.608 women). The eligible 
women were in the age range of 50–79 age and they 
were recruited between 1993–1998. The study arm with 
two-component HRT was closed after 5.6 years and with 
estrogens alone after 7.2 years. 
After 11 years of follow-up it was showen, that 
women receiving estrogens alone had a decreased risk 
Table 2. Relative risk of breast cancer development in 
women using hormone replacement therapy in the Million 
Women Study [51]
Duration of HRT Relative risk (95% CI)
Never using HRT
Previously using HRT:
shorter than 1 year
1–4 years
5–9 years
10 years and longer
Currently using oestrogens alone:
shorter than 1 year
1–4 years
5–9 years
10 years and long
Currently using oestrogens 
with progestogens:
shorter than 1 year
1–4 year
5–9 years
10 years and long
1.00 (0.96–1.04)
0.94 (0.84–1.05)
1.01 (0.92–1.12)
1.14 (1.00–1.30)
1.05 (0.84–1.30)
0.81 (0.55–1.20)
1.25 (1.10–1.41)
1.32 (1.20–1.46) 
1.37 (1.22–1.54)
1.45 (1.19–1.78) 
1.74 (1.60–1.89)
2.17 (2.03–2.33)
2.31 (2.08–2.56)
HRT — hormone replacement therapy; CI — confidence interval
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of breast cancer development (HR = 0.77, p = 0.02) and 
also the risk of death due to breast cancer (HR = 0.37, 
p = 0.03) as compared to placebo [44]. Contrary to this, 
the women taking estrogens combined with progesto-
gens had a increased risk of breast cancer development 
comparing to placebo (HR = 1.55, p < 0.001) and 
slightly increased risk of death due to breast cancer 
(HR = 1.32), however this difference was not statisti-
cally significant (p = 0.15) (Table 3) [43].
In 2013 up-dated results of WHI studies were pub-
lished after 13 years of follow-up [45]. They confirmed 
the increased risk of breast cancer development after 
two-component HRT (HR = 1.28, p < 0.001), although 
it was slightly lower than during previous analyses of this 
population. Additionally, comparing to placebo group 
decreased risk of breast cancer development was still 
seen (HR = 0.79). Mechanism of these differences was 
not explained until now (Table 4).
Table 3. Influence of hormone replacement therapy women health (based on the randomised clinical study Women’s Health 
Initiative [33–43])
Disease         Combined HRT 
(oestrogens/progestogens)
Oestrogens alone HRT
Morbidity risk (HR) Death risk (HR) Morbidity risk (HR) Death risk (HR)
Invasive breast cancer 1.55 1.32 0.77 0.37
Colorectal cancer 0.75    1.54                  1.11     0.99
Non-small cell lung cancer 1.23                      1.71 1.17     0.89
Endometrial cancer 0.78                          1.08
Ovarian cancer 1.58 –
Cervical cancer 1.44 –
Ischaemic heart disease 1.22 0.95
Stroke 1.34 1.36
Deep venous thrombosis 1.88 1.47
Pulmonary embolism 1.98 1.37
Cholelithiasis/cholecystitis 1.61 1.79
Urinary incontinence  1.39 1.53
Dementia 2.05 1.49
Bone fracture 0.76 0.70
HRT — hormone replacement therapy; HR — hazard ratio
Table 4. Updated results of the randomised Women’s Health Initiative study after 13 years of follow-up [44, 45]
Disease Combined HRT (oestrogens/progestogens) Oestrogens alone HRT
Morbidity risk (HR) p Morbidity risk (HR) p
Invasive breast cancer 1.28 < 0.01 0.79     0.02
Colorectal cancer 0.80 0.06 1.13     0.39
Non-small cell lung cancer 1.10 0.38 0.98     0.87
Endometrial cancer 0.67 0.01 –
Ovarian cancer 1.24 0.30 –
Coronary heart disease 1.09 0.19 0.94    0.43
Stroke 1.16 0.06 1.15    0.10
Deep venous thrombosis 1.24 0.40 1.05    0.71
Pulmonary embolism 1.26 0.05 1.15    0.34
Bone fracture 0.81 0.02 0.91    0.44
Death for any reason 0.99 0.87 0.99    0.92
Death from cardiovascular reasons 0.97 0.73 0.97    0.75
Cancer-related deaths 1.07 0.32 0.95    0.58
HR — hazard ratio
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Published in 2012 Cochrane meta-analysis of 23 clini-
cal trials including 42.830 women receiving either HRT 
or placebo confirmed the increased risk of breast cancer 
development after combined estrogens–progesteron 
therapy, but statistically significant increase of breast 
cancer development after estrogens alone was not 
shown [28].
Hormone replacement therapy (menopausal 
hormone therapy) in healthy women as prevention 
of cardiovascular disease
Based on over 40 publications presenting beneficial 
effect of HRT on cardiovascular system and skeleton as 
well as general well-being, HRT started to become wide-
ly used in primary and secondary prevention of neuro-
cognitive disorders and demention during ‘80s and ‘90s 
of last century. Additionally the time period of HRT 
administration was prolonged from 1–2 years (typical 
duration of HRT for menopausal symptoms control) up 
to 5–10 years or even longer [46]. However, randomized 
WHI clinical studies [33] did not confirm protective 
role of HRT on cardiovascular system. Increased risk of 
myocardial infarction, stroke, deep vein thrombosis and 
pulmonary embolism was noted. Beneficial influence of 
HRT on brain efficiency was also not confirmed.
Based on this and other studies [28, 29, 33] it was 
established, that two-component HRT should not be 
neither recommended nor continued in prevention of 
ischaemic heart disease (Table 3 and 4).
Hormone replacement therapy (menopausal 
hormone therapy)in patients with diagnosis of 
cardiovascular diseases
Randomized HERS (Heart and Estrogen/Progestin 
Replacement Study) clinical study [47] analysed the 
influence of combined HRT on the clinical course of 
ischaemic heart disease in 2763 women with previously 
diagnosed cardiovascular disease. This study did not 
confirm protective role of HRT, it was even shown 
higher percentage of cardiac complications in this 
female population [48]. During 6.8 years of follow-up 
in HERS II clinical trial [48] no decrease in the risk of 
cardiovascular complications in women with ischaemic 
heart disease using HRT was shown (RR = 0.99).
Cochrane meta-analysis of 23 clinical trials includ-
ing 42830 women receiving either HRT or placebo 
— published in 2012 — confirmed the increased risk 
of thromboembolic complications after combined 
estrogen–progesteron therapy in women with cardio-
vascular diseases [28]. Based on foregoing results HRT 
is not recommended for using in order to decrease of 
ischaemic heart disease risk in cardiovascular disease 
patients [25–27]. 
Who is the best candidate to hormone 
replacement therapy/menopausal 
hormone therapy?
In 2012–2013 the indications for HRT were updated. 
According to the U.S. Preventive ServicesTask Force 
[29], the U.S. Food and Drug Administration [25], the 
International Menopause Society, and seven other 
scientific societies (the American Society for Reproduc-
tive Medicine, the Asia Pacific Menopause Federation, 
the Endocrine Society, the European Menopause and 
Andropause Society, the International Menopause 
Society, the International Osteoporosis Foundation, 
and the North American Society) [26] and the British 
Menopause Society [27], the most important indications 
for HRT are vasomotor symptoms of menopause; less 
frequently it is indicated for the prevention of fracture 
resulted from osteoporosis in patients with high risk of 
fracture, not tolerating other treatment options. 
Before initiation of HRT healthy women should be 
informed in detail about the risk-benefit balance related 
to the preparations used, and the individual cumula-
tive risk should be estimated. Detailed medical history 
should also be considered with special attention to risk 
factors of breast cancer development and cardiovascular 
disease. The final decision regarding HRT should be 
made by the patient based on risk-benefit assessment. 
The exact time period of HRT administration has 
not been established to date. It is determined on an 
individual basis, depending on intensity of symptoms 
and individual risk of complications (thromboembolic 
disease, stroke, ischaemic heart disease, and breast can-
cer) [26, 27]. In healthy women, who have no significant 
increase in the risk of breast cancer and cardiovascular 
diseases, the duration of HRT should be limited to the 
period with maintenance of menopausal symptoms. The 
risk-benefit ratio should be repeatedly assessed after 
each therapy year, and based on this the decision about 
continuation or termination of HRT should be made. 
Total therapy time period should be as short as possible.
Hormone replacement therapy (menopausal 
hormone therapy) in breast cancer patients
There is only sparse scientific evidence regarding 
the risk of cancer recurrence and death after HRT in 
women with breast cancer.
In 2006 a pooled analysis of 15 clinical trials was 
published, including seven controlled studies, which 
involved 1416 female patients with breast cancer using 
HRT [49]. The analysis showed that HRT does not 
increase the risk of disease recurrence and death due 
to cancer in this population. 
To date there have been two randomised clinical 
trials only analysing the risk of HRT in breast cancer 
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patients. The HABITS study enrolled 447 patients. This 
trial was stopped after interim analysis showing a dou-
bling of the disease recurrence (HR = 2.4) [50]. Final 
risk [51] was 3.5-fold higher as compared with women 
not receiving HRT. The second randomised Stockholm 
study indicated a higher risk of second breast cancer 
(HR = 3.6), despite initial suggestions regarding lack 
of risk of primary cancer progression (HR = 0.82) [52]. 
Since 2013 eight scientific societies (the Interna-
tional Menopause Society, the American Society for 
Reproductive Medicine, the Asia Pacific Menopause 
Federation, the Endocrine Society, the European 
Menopause and Andropause Society, the International 
Menopause Society, the International Osteoporosis 
Foundation, andthe North American Society) have not 
recommended HRT in patients with current or recent 
breast cancer [26].
The present statement is much more restrictive than 
previous versions, in which the use of trial HRT in breast 
cancer patients with intense menopausal symptoms was 
permitted for 1–3 months and could be continued for 
1–2 years in case of clinical improvement. However, the 
patient had to be informed about and accept a 30% in-
creasing of the risk of breast cancer recurrence. Current 
publications do not contain such a recommendation.
Hormone replacement therapy — summary
1. The most important indication to HRT in healthy 
women are vasomotor menopausal symptoms. Hor-
mone replacement is the most effective method of 
preventing and managing such complaints.
2. The second indication to HRT is the treatment and 
prevention of osteoporosis in selected patients, with 
failure after other drugs.
3. Hormone repalacement therapy should not be 
used for primary and secondary prevention of car-
diovascular diseases because there is no preventive 
effect for cardiovascular disease. Oestrogens and 
progestogens increase the risk of stroke, pulmonary 
embolism, and thromboembolic disease. There is 
also no evidence that HRT is efficient if prevention 
of neurocognitive disorders and dementia.
4. Combined oestrogen–progestogen HRT increases 
the risk of breast cancer development in healthy 
women, whereas oestrogens alone decrease this risk. 
5. Genetic counselling centres advise against the use of 
HRT by healthy carriers of BRCA1/2 gene mutations, 
because of the cumulative risk of breast cancer devel-
opment and cardiovascular disease, related to strong 
hereditary predisposition to this cancer and age.
6. HRT is not recommended in breast cancer patients. 
Figures 1 and 2 presentsthe current statement 
regarding use of OC and HRT in connection with 
breast cancer.
Alternative methodsof vasomotor symptoms 
reduction
Many non-hormone treatment methods were eval-
uated with regard to reducing vasomotor symptomsof 
menopause, but only a few of them delivered any clinical 
benefit. Up to now the following methods have been 
studied: lifestyle modification (physical exercise), phy-
toestrogen-rich diet (soy), non-hormone drugs (selective 
serotonin reuptake inhibitors, SSRIs, and serotonin-nor-
epinephrine reuptake inhibitors, SNRIs, gabapentin), 
behavioural therapy (cognitive behavioural therapy, 
relaxation techniques, yoga),as well as alternative 
medicine (acupuncture) [53, 54]. Analyses of numerous 
non-randomised trials as well as meta-analyses indicated 
that currently there is a lack of evidence confirming the 
efficacy of physical exercise, phytoestrogen-rich diet, or 
dietary supplements in reducing of vasomotor symptoms 
of menopause [53]. Similarly, too few publications ded-
icated to behavioural therapy and alternative medicine 
make their efficacy impossible to assess. 
SSRIs, SNRIs, and gabapentin are the most efficient 
in reducing of vasomotor symptoms, especially hot 
flushes [53, 54]. Drugs from the SSRI group (paroxetine, 
Figure 1. Principles of oral contraception depending on the risk of breast cancer development in young women — oral hormone 
contraception
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Figure 2. Principles of oral contraception depending on the risk of breast cancer development in peri- and postmenopausal 
women — hormone replacement therapy
escitalopram, citalopram, and sertraline) sufficiently 
decrease the frequency and intensity of hot flushes, 
and paroxetine is the most potent drug out of them. 
Venlafaxine (SNRI) were also shown to effectively treat 
menopausal symptoms, together with the most frequent 
like lack of appetite, nausea, and constipation. Gabapen-
tin, a gamma-aminobutyric acid (GABA) analogue, is 
also effective in alleviating of menopausal and other 
symptoms due to tamoxifen administration; however, 
dizziness, heart palpitations, fatigue, and peripheral 
oedema are very frequent side effects. Alpha-2 adren-
ergic receptor agonist, clonidine, is another drug used 
in patients with hot flushes, but it results in dry mouth, 
constipation, and sleep disorders. Beta-blockers reduce 
anxiety and heart palpitations, but with no influence on 
hot flushes. All pharmacological methods mentioned 
above were evaluated in the treatment of hot flushes 
not only in healthy women but also in patients with 
breast cancer. Despite the effectiveness in a portion of 
the women, none of them was as effective as hormone 
preparations [53].
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